24468-88-0

Usage

Uses

Used in Organic Synthesis:
N-Benzyl-2-bromo-N-(2-bromoethyl)ethanamine is used as an intermediate in the synthesis of various organic compounds, leveraging its bromo substituents for reactivity in chemical reactions.
Used in Pharmaceutical Research:
In the pharmaceutical industry, N-Benzyl-2-bromo-N-(2-bromoethyl)ethanamine serves as a key intermediate in the production of different pharmaceuticals, contributing to the development of new drugs.
Used in Drug Discovery and Development:
Due to its pharmacological properties, N-Benzyl-2-bromo-N-(2-bromoethyl)ethanamine is a subject of interest in drug discovery and development, potentially leading to the creation of novel therapeutic agents.

InChI:InChI=1/C11H15Br2N/c12-6-8-14(9-7-13)10-11-4-2-1-3-5-11/h1-5H,6-10H2

Upstream product

• 91335-65-8 N,N-bis-(2-bromo-ethyl)-benzamide 
• 98-88-4 benzoyl chloride 
• 101-32-6 N-benzyl-diethanolamine 
• 100-39-0 benzyl bromide 

Downstream Products

• 99573-07-6 N,N-bis(2-(diphenylphosphino)ethyl)benzylamine 
• 1419389-16-4 C₂₂H₂₅NO₃ 
• 1419389-20-0 C₂₂H₁₉F₆NO₇S₂ 

Relevant academic research and scientific papers

Compound serving as SHP2 inhibitor and application thereof

The invention belongs to the field of medical chemistry, relates to a compound serving as an SHP2 inhibitor and an application of the compound, and particularly provides a compound shown in a formula (I) or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug of the compound, processes for the preparation, pharmaceutical compositions containing these compounds and the use of these compounds or compositions for the treatment of SHP2 mediated diseases.

SHP2 INHIBITORS, COMPOSITIONS AND USES THEREOF

Provided herein are compounds of Formula (I), methods of using the compounds as SHP2 inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating SHP2-mediated diseases.

IMIDAZOPYRIMIDINE DERIVATIVES

The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating cancers.

NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS

Provided is a compound of formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, provided is a pharmaceutical composition comprising the said compound.

Pyrazinothiazole compound and application thereof, and pharmaceutical composition containing pyrazinothiazole compound

The invention discloses a pyrazinothiazole compound, an application of the pyrazinothiazole compound, and a pharmaceutical composition containing the pyrazinothiazole compound, and provides a pyrazinothiazole compound represented by a formula A or a pharmaceutically acceptable salt of the pyrazinothiazole compound. The pyrazinothiazole compound provided by the invention has relatively good SHP2 inhibitory activity.

Novel heterocyclic derivative capable of being used as SHP2 inhibitor

The invention relates to a novel heterocyclic derivative capable of being used as an SHP2 inhibitor, specifically relates to a compound shown by a formula I or pharmaceutically acceptable salts thereof, further relates to a use of the compound shown by the formula I or the pharmaceutically acceptable salts thereof and a pharmaceutical composition thereof in drug preparation, and particularly relates to a use in preparation of drugs for treatment, inhibition or prevention of diseases or discomforts mediated by SHP2 activity.

METHODS USING HDAC11 INHIBITORS

The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.

NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS

This invention relates to certain novel pyrazine derivatives (Formula I) as SHP2 inhibitors which is shown as formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, this invention is directed to fused heterocyclic group derivatives useful as inhibitors of SHP2, methods for producing such compounds and methods for treating a SHP2-mediated disorder.

SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS

Disclosed are spiro compounds of formula (I), or stereomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof. The compounds can be used to treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore disclosed are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions in the treatment of HCV infection or hepatitis C disease.

Dual coordination modes of ethylene-linked NP2 ligands in cobalt(II) and nickel(II) iodides

Here we report the syntheses and crystal structures of a series of cobalt(II) and nickel(II) complexes derived from RNP2 ligands (where R = OMeBz, HBz, BrBz, Ph) bearing ethylene linkers between a single N and two P donors. The CoII complexes generally adopt a tetrahedral configuration of general formula [(NP2)Co(I) 2], wherein the two phosphorus donors are bound to the metal center but the central N-donor remains unbound. We have found one case of structural isomerism within a single crystal structure. The CoII complex derived from BzNP2 displays dual coordination modes: one in the tetrahedral complex [(BzNP2)Co(I)2]; and the other in a square pyramidal variant, [(BzNP2)Co(I)2]. In contrast, the NiII complexes adopt a square planar geometry in which the P(Et)N(Et)P donors in the ligand backbone are coordinated to the metal center, resulting in cationic species of formula [(RNP2)Ni(I)]+ with iodide as counterion. All NiII complexes exhibit sharp 1H and 31P spectra in the diamagnetic region. The Co II complexes are high-spin (S = 3/2) in the solid state as determined by SQUID measurements from 4 to 300 K. Solution electron paramagnetic resonance (EPR) experiments reveal a high-spin/low-spin CoII equilibrium that is dependent on solvent and ligand substituent.